NCT04895748CompletedPhase 1
Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Dec 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- First submitted
- 2 May 2024
- Start date
- 26 Jan 2021
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Kidney cancer
- NCT number
- NCT04895748
- EU CT number
- 2024-513379-41-00
- EudraCT number
- 2020-004383-25
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 28
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Masarykuv Onkologicky Ustav Coordinator of this site? Confirm its status | Brno-Stred | Czechia | Completed |
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.